POSITRON-EMISSION-TOMOGRAPHY WITH F-18 DEOXYGLUCOSE IN PATIENTS WITH DIFFERENTIATED THYROID-CARCINOMA, ELEVATED THYROGLOBULIN LEVELS, AND NEGATIVE IODINE SCANS
G. Altenvoerde et al., POSITRON-EMISSION-TOMOGRAPHY WITH F-18 DEOXYGLUCOSE IN PATIENTS WITH DIFFERENTIATED THYROID-CARCINOMA, ELEVATED THYROGLOBULIN LEVELS, AND NEGATIVE IODINE SCANS, LANGENBECKS ARCHIVES OF SURGERY, 383(2), 1998, pp. 160-163
Introduction: In patients with differentiated thyroid carcinoma, eleva
ted serum levels of thyroglobulin (hTg) may occur in spite of otherwis
e negative diagnostic procedures and in particular in spite of a negat
ive iodine-131 scan. Positron emission tomography with F-18-deoxygluco
se (FDG-PET) is a potentially useful method for the detection of metas
tatic lesions or the recurrence of thyroid cancer. We aimed to investi
gate whether FDG-PET is capable of detecting metastastic lesions or re
currence in patients with differentiated thyroid carcinoma, elevated s
erum levels of thyroglobulin, and otherwise negative diagnostic proced
ures, including the iodine-131 scan. Methods: From a group of 500 pati
ents with differentiated thyroid carcinoma, a subgroup of 32 patients
had elevated serum hTg-levels, negative iodine-131 scans, negative cer
vical and abdominal ultrasound, and negative X-ray of the chest. In 12
of these patients (hTg 77.8+/-94.3 ng/ml. range 1.5-277 ng/ml, median
20 ng/ml), FDG-PET was per formed. All but one FDG-PET study was perf
ormed in a state of hypothyroidism (TSH 75.8+/-32.2 mu IU/ml, range 31
- 116 mu IU/ml, median 74.6 mu IU/ml). Results: In 6 of the 12 patien
ts investigated, the FDG-PET was positive. In three of the patients, t
he diagnosis was confirmed by computed tomography or magnetic resonanc
e imaging. In patients with a positive FDG-PET finding, the hTg level
was 146.7+/-90.1 ng/ml (23-277 ng/ml, median 144.5 ng/ml). In contrast
, in patients with a negative finding the hTg level was only 9.0+/-7.6
ng/ml (range 1.5-17 ng/ml, median 8.1 ng/ml), P=0.01. Conclusion: The
se preliminary results show that in patients with differentiated thyro
id carcinoma, elevated hTg levels, and otherwise negative ''convention
al'' diagnostic procedures, FDG-PET is helpful in detecting metastatic
lesions.